Physiomics PLC Presentation at Conference on Pharmacometrics
October 26 2016 - 2:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
26 October 2016
Physiomics plc
("Physiomics") or ("the Company")
Physiomics to give an oral presentation on developments of the
Virtual Tumour platform in drug resistance at the Seventh American
Conference on Pharmacometrics ("ACoP7")
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology
Company, is pleased to announce that it is participating in the
ACoP7 Meeting 2017, taking place at the Hyatt Regency Bellevue,
Washington on 24-26 October 2016. Dr David Orrell, Principal
Consultant, will present on the application of the Virtual Tumour
("VT") platform to predict the emergence of resistance.
Drug resistance is a major cause of treatment failure in cancer,
and understanding and overcoming mechanisms of resistance is a key
challenge in advancing cancer therapy. Given the significance of
cancer drug resistance, and the form that future cancer therapy is
likely to take, Physiomics is actively engaged in developing
personalised medicine solutions.
As a first step, we have incorporated chemotherapeutic
resistance into our Virtual Tumour platform. This VT extension
captures the fundamental mechanism by which resistance arises.
Through a case study, we have demonstrated that the extended VT
can be applied to model the emergence of resistance in
patient-derived xenografts. Furthermore, we show that the VT can be
used to identify and optimise therapeutic strategies for delaying
the emergence of drug resistance. Such a tool could help at the
patient level to improve a key clinical metric, the "time to
relapse", i.e. how long it takes for a patient to become resistant
to a given treatment.
David Orrell is an applied mathematician, with a PhD from Oxford
University on the prediction of nonlinear systems. He has worked in
diverse areas including weather forecasting, economics, and systems
biology, and at Physiomics is working on model development. He has
written over 20 research papers, and is the author of several books
including "The Future of Everything: The Science of
Prediction".
The abstract ("Modelling the Emergence of Resistance to
Chemotherapeutics with Virtual Tumour", No W-24) will be presented
in the Poster Session #3, scheduled 7:30 AM-9:30 AM, 26 October
2016.
More information about the conference may be found at:
http://www.acop7.org/home
Dr Christophe Chassagnole, COO of Physiomics, commented:
"We are pleased to present for the first time at the American
Conference on Pharmacometrics, which is the main US conference for
PK/PD modelling. The company will be represented by David Orrell,
the inventor of the Virtual Tumour technology. The ability to
reduce the appearance of drug resistance via optimised scheduling
could potentially play an important role in increasing patient
survival."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (Co-broker/nomad)
Katy Mitchell
+44 (0) 161 832 2174
Hybridan LLP
Claire Louise Noyce (Co-Broker)
+44 (0) 203 764 2341
About Physiomics plc
Physiomics (AIM:PYC) is a computational systems biology services
company applying simulations of cell behaviour to drug development
to reduce the high attrition rates of clinical trials. 80-90 per
cent of all clinical drug candidates fail to reach the market and
estimates show that an overall ten per cent improvement in success
rates could reduce the cost of one drug's development by as much as
$242 million, from the current estimate of around $800 million(1)
.
Physiomics develops computational systems biology models to
predict and understand cancer drug efficacy from pre-clinical
research to clinical development. Physiomics has created detailed
mathematical models incorporating the most important molecular
events taking place during the human cell cycle and apoptosis
processes. The company's SystemCell(R) technology enables the
simulation of populations of "virtual cells". The company has also
developed a "Virtual Tumour" model to simulate the effect of
anti-cancer drugs on tumour growth. The models are used to optimise
compound design and to design drug schedules and combination
therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and
floated on AIM in 2004. For further information, please visit
www.physiomics-plc.com
SystemCell(R) is a registered trademark of Physiomics plc
(1) Tufts Centre Impact Report 2002
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEADESALNKFFF
(END) Dow Jones Newswires
October 26, 2016 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Physiomics (LSE:PYC)
Historical Stock Chart
From Apr 2023 to Apr 2024